JPS62501399A - 腫瘍転移に関連した伝播性を有するほ乳類遺伝子 - Google Patents

腫瘍転移に関連した伝播性を有するほ乳類遺伝子

Info

Publication number
JPS62501399A
JPS62501399A JP60505382A JP50538285A JPS62501399A JP S62501399 A JPS62501399 A JP S62501399A JP 60505382 A JP60505382 A JP 60505382A JP 50538285 A JP50538285 A JP 50538285A JP S62501399 A JPS62501399 A JP S62501399A
Authority
JP
Japan
Prior art keywords
cells
dna
metastasis
mammalian
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP60505382A
Other languages
English (en)
Japanese (ja)
Inventor
バーンステイン,シエリー・シー
ウエインバーグ,ロバート・エイ
Original Assignee
ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ filed Critical ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ
Publication of JPS62501399A publication Critical patent/JPS62501399A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP60505382A 1984-11-30 1985-11-26 腫瘍転移に関連した伝播性を有するほ乳類遺伝子 Pending JPS62501399A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67662584A 1984-11-30 1984-11-30
US676625 1984-11-30

Publications (1)

Publication Number Publication Date
JPS62501399A true JPS62501399A (ja) 1987-06-11

Family

ID=24715276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60505382A Pending JPS62501399A (ja) 1984-11-30 1985-11-26 腫瘍転移に関連した伝播性を有するほ乳類遺伝子

Country Status (13)

Country Link
EP (1) EP0203970A1 (enrdf_load_stackoverflow)
JP (1) JPS62501399A (enrdf_load_stackoverflow)
AU (1) AU5197986A (enrdf_load_stackoverflow)
DK (1) DK359486D0 (enrdf_load_stackoverflow)
ES (1) ES8705043A1 (enrdf_load_stackoverflow)
FI (1) FI863095A0 (enrdf_load_stackoverflow)
GR (1) GR852864B (enrdf_load_stackoverflow)
HU (1) HUT41837A (enrdf_load_stackoverflow)
IL (1) IL77157A0 (enrdf_load_stackoverflow)
NO (1) NO863066L (enrdf_load_stackoverflow)
PT (1) PT81584B (enrdf_load_stackoverflow)
WO (1) WO1986003226A1 (enrdf_load_stackoverflow)
ZA (1) ZA859070B (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049662A (en) * 1987-10-13 1991-09-17 The United States Of America As Represented By The Department Of Health And Human Services Kit for diagnosing cancer metastatic potential
DE69033810T2 (de) * 1989-10-18 2002-03-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
US6825320B1 (en) 1995-03-29 2004-11-30 Millenium Pharmaceuticals, Inc. FOHY03 polypeptides
US6794185B1 (en) 1995-03-29 2004-09-21 Millennium Pharmaceuticals, Inc. fohy030 nucleic acid molecules
US6251597B1 (en) 1996-03-29 2001-06-26 Millennium Pharmaceuticals, Inc. Methods for detecting fohy030
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
US5783182A (en) * 1996-01-30 1998-07-21 Baylor College Of Medicine Method for identifying metastatic sequences
WO1997018454A2 (en) * 1995-11-16 1997-05-22 Baylor College Of Medicine Method for identifying metastatic sequences
EP0873424B1 (en) * 1996-01-10 2004-08-25 The University Of Liverpool Metastasis inducing dna's
USRE38392E1 (en) 1996-01-30 2004-01-20 Baylor College Of Medicine Method for identifying metastatic sequences
US6312909B1 (en) 1996-03-29 2001-11-06 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis prevention and treatment of tumor progression
EP1029048A2 (en) 1997-11-05 2000-08-23 Baylor College Of Medicine Sequences for targeting metastatic cells
CA2323074A1 (en) 1998-03-13 1999-09-16 Baylor College Of Medicine Compositions and methods for the treatment and prevention of metastatic disorders
US7462491B2 (en) 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin

Also Published As

Publication number Publication date
FI863095A7 (fi) 1986-07-29
NO863066L (no) 1986-09-29
HUT41837A (en) 1987-05-28
DK359486A (da) 1986-07-29
DK359486D0 (da) 1986-07-29
PT81584B (en) 1987-04-07
FI863095L (fi) 1986-07-29
ES549438A0 (es) 1987-04-16
GR852864B (enrdf_load_stackoverflow) 1986-03-28
FI863095A0 (fi) 1986-07-29
IL77157A0 (en) 1986-04-29
WO1986003226A1 (en) 1986-06-05
EP0203970A1 (en) 1986-12-10
ES8705043A1 (es) 1987-04-16
PT81584A (en) 1985-12-01
ZA859070B (en) 1986-07-30
NO863066D0 (no) 1986-07-29
AU5197986A (en) 1986-06-18

Similar Documents

Publication Publication Date Title
JPS62501399A (ja) 腫瘍転移に関連した伝播性を有するほ乳類遺伝子
AU2016201051B2 (en) Methods and compositions for diagnosis and treatment of cancer
CN109414408A (zh) 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
CN102325548A (zh) 用于癌症的诊断和治疗的方法和组合物
US8771705B2 (en) Combination of protein vaccine and mesenchymal stem cells for treating cancer
CN103937872A (zh) Crm1在胃癌诊断与治疗中的应用
CN111617249B (zh) hsa_circ_0007444在制备治疗卵巢癌的药物中的应用
CN111996251A (zh) 一种恶性胶质瘤生物标志物的应用
CN106701902B (zh) Foxr2基因和表达产物在肝癌诊断与治疗中的应用
CN103937871B (zh) Srrp35基因和表达产物在癌症诊断与治疗中的应用
CN109562121A (zh) 转移性癌症的诊断和治疗方法
CN111254130A (zh) Ddx24解旋酶点突变抑制肿瘤生长的方法及其应用
CN116656583A (zh) 靶向肿瘤的幽门螺杆菌突变株及抗胃癌外膜囊泡组合物
CN113293208B (zh) 与肺癌增殖和转移相关的分子标志物及其应用
CN106701904B (zh) Acsl4基因和表达产物在胃癌诊断与治疗中的应用
CN110893240B (zh) Nme2基因在抑制禽呼肠病毒复制中的应用
CN116670172A (zh) 表达免疫检查点抑制剂的癌症特异性反式剪接核酶及其用途
CN101712960A (zh) Mac-2BP肿瘤抗原基因、蛋白、抗体及其用途
CN101363027B (zh) 携带短发夹rna的重组质粒的制备方法及用途
CN115141828B (zh) 干扰SQR基因的shRNA及其应用
CN114272378B (zh) 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途
CN110747197B (zh) 一种人内源性27nt-miRNA分子在制备抗肿瘤药物中的应用
WO2025077854A1 (zh) 一种新型微肽mp36及其应用
CN119286940A (zh) 一种可表达增强型绿色荧光蛋白的人胸腺瘤细胞系及制备方法
CN119639754A (zh) mRNA及其合成方法、mRNA疫苗、加帽RNA、体外转录反应液